SERUM CYSTATIN C IN MURINE TUMORS TREATED BY COMBINATIONS OF CYCLOPHOSPHAMIDE WITH UKRAIN OR GLUCANS
USOVA Т.А.1, POTERYAEVA O.N.2, FALAMEYEVA O.V.1, ZHANAEVA S.Y.1, LEVINA O.A.1, YARYGINA E.S.1, KOROLENKO T.A.1, NOWICKY J.3
1) Institute of Physiology, Siberian Branch of Russian Academy of Medical Sciences, Novosibirsk, Russia.
2) Institute of Biochemistry, Siberian Branch of Russian Academy of Medical Sciences, Novosibirsk, Russia.
3) Ukrainian Anti-Cancer Institute, Vienna, Austria.
Address for correspondence: T.A. Usova, Laboratory of Cellular Biochemistry, Institute of Physiology, Russian Academy of Medical Sciences, ul. Timakova 4, 630117 Novosibirsk, Russia.
Summary: The antitumor drug Ukrain exerted malignotoxic effect in vivo and was effective in the treatment of some malignancies in experimental animals as a result of immunostimulation. Serum concentration of cystatin C, an endogenous cysteine protease inhibitor, was measured in a murine tumor model of Lewis lung adenocarcinoma during cyclophosphamide treatment combined with Ukrain or glucans. It was shown that in murine Lewis lung adenocarcinoma serum cystatin C concentration decreased approximately 2-fold, while Ukrain treatment combined with cyclophosphamide restored serum cystatin C levels to the normal value. Similar results were obtained using a combination of cyclophosphamide with some glucans, biological response modifiers.